Director Therapeutic Expertise Team
Leyla is a scientific , operational and strategic leader. She has 10+ years of experience and is a member of ReSViNET’s board of directors. Under her guidance, this talented and dedicated group of scientists and professionals can create a customized plan for the evaluation of your treatment at a global scale.
We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:
– Pandemic preparedness – lessons learned
– Clinical Development for new COVID-19 vaccines
– Known and Unknown” Unknowns
Watch the replay now
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme to make new and improved vaccines accessible to low- and middle-income countries.
With a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, IVI works with other product development partners to take innovative vaccine technology from need to impact. IVI developed the world’s first low-cost oral cholera vaccine, manufactured by three different companies and pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI’s portfolio includes vaccines at all stages of pre-clinical and clinical development for diseases of global health importance such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, Hepatitis E, HPV, and COVID-19.
IVI is headquartered in Seoul, Republic of Korea with a European Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.
During this webinar, hosted by Billy Franks, Prof. Miriam Sturkenboom (UMC Utrecht, the Netherlands) discussed: - The need for a readily available data and analytics network in Europe for generating safety insights and conducting safety assessm...
A new area of outsourcing: Improve efficiency and streamline trail solutions with a personalized approach to clinical trial solution
Personalization is the new king of global outsourcing. Patients are crying out for more flexible, more diverse and less burdensome trial designs, while the ever larger CROs become less versatile with every merger. It’s no surprise that pharma is...